[go: up one dir, main page]

MXPA03002546A - Fenoxifenilalcanosulfonatos. - Google Patents

Fenoxifenilalcanosulfonatos.

Info

Publication number
MXPA03002546A
MXPA03002546A MXPA03002546A MXPA03002546A MXPA03002546A MX PA03002546 A MXPA03002546 A MX PA03002546A MX PA03002546 A MXPA03002546 A MX PA03002546A MX PA03002546 A MXPA03002546 A MX PA03002546A MX PA03002546 A MXPA03002546 A MX PA03002546A
Authority
MX
Mexico
Prior art keywords
phenoxyphenyl
alkane sulfonates
sulfonates
diseases
relates
Prior art date
Application number
MXPA03002546A
Other languages
English (en)
Inventor
Markus Heil
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MXPA03002546A publication Critical patent/MXPA03002546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/20—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C309/22—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion se refiere a fenoxifenilalcanosulfonatos de formula (I) (en la que A significa oxigeno o NH, y R3 significa alquilo (C4-C7) que puede estar sustituido una o varias veces con fluor o cloro), a procedimientos para su preparacion, a su uso para la preparacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades, especialmente para el tratamiento de estados de dolor y enfermedades neurodegenerativas.
MXPA03002546A 2000-09-26 2001-09-13 Fenoxifenilalcanosulfonatos. MXPA03002546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10047486A DE10047486A1 (de) 2000-09-26 2000-09-26 Phenoxyphenyl Alkansulfonate
PCT/EP2001/010564 WO2002026702A1 (de) 2000-09-26 2001-09-13 Phenoxyphenyl alkansulfonate

Publications (1)

Publication Number Publication Date
MXPA03002546A true MXPA03002546A (es) 2004-04-20

Family

ID=7657564

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002546A MXPA03002546A (es) 2000-09-26 2001-09-13 Fenoxifenilalcanosulfonatos.

Country Status (34)

Country Link
US (2) US6756409B2 (es)
EP (1) EP1334086B1 (es)
JP (1) JP2004509946A (es)
KR (1) KR20030039372A (es)
CN (1) CN1476427A (es)
AR (1) AR033575A1 (es)
AT (1) ATE292621T1 (es)
AU (2) AU2002220547B2 (es)
BG (1) BG107634A (es)
BR (1) BR0114182A (es)
CA (1) CA2423171A1 (es)
DE (2) DE10047486A1 (es)
EE (1) EE200300117A (es)
ES (1) ES2240543T3 (es)
GT (1) GT200100193A (es)
HN (1) HN2001000214A (es)
HR (1) HRP20030326A2 (es)
HU (1) HUP0302258A3 (es)
IL (1) IL154968A0 (es)
MA (1) MA26053A1 (es)
MX (1) MXPA03002546A (es)
NO (1) NO20031357L (es)
NZ (1) NZ524886A (es)
PE (1) PE20020408A1 (es)
PL (1) PL361015A1 (es)
PT (1) PT1334086E (es)
RU (1) RU2278853C2 (es)
SI (1) SI1334086T1 (es)
SK (1) SK3442003A3 (es)
SV (1) SV2002000639A (es)
UA (1) UA75369C2 (es)
UY (1) UY26945A1 (es)
WO (1) WO2002026702A1 (es)
ZA (1) ZA200302275B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
CN102149379A (zh) * 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
US10709497B2 (en) * 2017-09-22 2020-07-14 Covidien Lp Electrosurgical tissue sealing device with non-stick coating
MX2021012250A (es) 2019-04-11 2022-01-18 Angion Biomedica Corp Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE216642C (es) *
BE786644A (fr) * 1971-07-23 1973-01-24 Hoechst Ag Derives d'acides phenoxy-4 phenoxy-alcane-carboxyliques leur preparation et les medicaments qui en contiennent
US3914418A (en) * 1971-09-02 1975-10-21 Merck & Co Inc Methods of controlling liver fluke infections
GB8914660D0 (en) * 1989-06-26 1989-08-16 Fujisawa Pharmaceutical Co Aniline derivatives,processes for production thereof and pharmaceutical compositions comprising the same
MY117939A (en) * 1996-07-25 2004-08-30 Lg Chemical Ltd Composition for enhancing oral hygiene
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
JP4346113B2 (ja) * 1997-02-21 2009-10-21 バイエル・アクチエンゲゼルシヤフト アリールスルホンアミド及びそれらの類似体並びに神経変性疾患の治療におけるそれらの使用
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
CA2305734A1 (en) * 1997-10-20 1999-04-29 Taisho Pharmaceutical Co., Ltd. 2-phenoxyaniline derivatives
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
NL1008795C2 (nl) * 1998-04-02 1999-10-05 Rene Werenfridus Lodewijk Vroo Samenstelling voor het behandelen van hoeven en werkwijze voor het vervaardigen van de samenstelling.
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases

Also Published As

Publication number Publication date
CA2423171A1 (en) 2003-03-21
ZA200302275B (en) 2004-03-24
IL154968A0 (en) 2003-10-31
CN1476427A (zh) 2004-02-18
RU2278853C2 (ru) 2006-06-27
ES2240543T3 (es) 2005-10-16
GT200100193A (es) 2002-06-04
HUP0302258A2 (hu) 2003-11-28
SK3442003A3 (en) 2003-10-07
NZ524886A (en) 2005-09-30
MA26053A1 (fr) 2004-04-01
HRP20030326A2 (en) 2005-02-28
JP2004509946A (ja) 2004-04-02
HN2001000214A (es) 2001-10-25
HUP0302258A3 (en) 2006-02-28
KR20030039372A (ko) 2003-05-17
UA75369C2 (en) 2006-04-17
US20030022934A1 (en) 2003-01-30
BG107634A (bg) 2003-12-31
AU2054702A (en) 2002-04-08
SI1334086T1 (en) 2005-10-31
NO20031357D0 (no) 2003-03-25
ATE292621T1 (de) 2005-04-15
BR0114182A (pt) 2003-07-29
DE10047486A1 (de) 2002-04-11
PL361015A1 (en) 2004-09-20
WO2002026702A1 (de) 2002-04-04
EP1334086B1 (de) 2005-04-06
NO20031357L (no) 2003-03-25
DE50105857D1 (de) 2005-05-12
UY26945A1 (es) 2002-04-26
US6756409B2 (en) 2004-06-29
EP1334086A1 (de) 2003-08-13
AU2002220547B2 (en) 2006-11-02
PE20020408A1 (es) 2002-06-08
AR033575A1 (es) 2003-12-26
EE200300117A (et) 2005-04-15
PT1334086E (pt) 2005-08-31
US20040214886A1 (en) 2004-10-28
SV2002000639A (es) 2002-10-24

Similar Documents

Publication Publication Date Title
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
MY135841A (en) Novel benzodioxoles
MXPA04003796A (es) Tioacetamidas sustituidas.
TNSN06228A1 (en) Compounds and methods of use
MY139552A (en) Phenethanolamine derivatives for treatment of respiratory diseases
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
MXPA02011288A (es) Tioacetamidas substituidas.
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
DE602004011394D1 (en) Thiazolderivate
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ATE325824T1 (de) Fluorhaltige copolymere, deren herstellung und verwendung
MXPA05012437A (es) Composiciones, dispositivos y metodos para estabilizar e intensificar la eficacia del dioxido de halogeno.
NZ524742A (en) Bridged piperazine derivatives
MXPA03002546A (es) Fenoxifenilalcanosulfonatos.
TW200504038A (en) 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors
EA200401423A1 (ru) Пиперазинбензотиазолы, используемые в качестве средств для лечения церебральных ишемических расстройств или расстройств цнс
MX2023014530A (es) Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.

Legal Events

Date Code Title Description
FG Grant or registration